How can Europe move from being a user of AI technologies to becoming a global leader in the development and deployment of artificial intelligence? This is one of the key questions that will be addressed at the Economic AI & HPC Forum, a strategic dialogue organized by MIPRO and CroAI.

Can a child’s drawing come to life in just a few seconds? Can a computer be controlled using only hand movements? Answers to these and many other questions will be revealed at a unique STEM event designed to delight children—and their parents.

A hands-on demonstration of the technology provides a first-hand insight into the world of robotics.

Fighting tumors that become resistant to therapy requires new drugs that block their growth, and the first crucial step is to identify, in the laboratory, new molecules that can precisely hit their targets.

This work reflects a growing scientific effort to better understand the neurobiology of trauma and to identify new therapeutic strategies for conditions that remain challenging to treat.

Our researchers Nenad Mijić, Abhiram Kaushik, Dario Zivkovic and Davor Davidovic in their newly published paper "Scalable QR Factorization of Ill-Conditioned Tall-and-Skinny Matrices on Distributed GPU Systems, (Journal MDPI Mathematics)" have developed a new way to handle one of the trickiest problems in scientific computing: working with huge, unstable datasets that normally break traditional math methods.

Computer Science Seminar, organized by the Centre for Informatics and Computing (IRB), aims to present ongoing research and discuss current topics and emerging trends in the field of computer science. Through lectures, case studies, and open discussions, participants gain insights into areas such as high-performance computing, artificial intelligence, data science, and software engineering. The event serves as a platform for knowledge exchange, networking, and exploring future directions in this field.

The BRAFV600E mutation is a major oncogenic driver found in melanoma, thyroid cancer, colorectal cancer, and several other malignancies — representing ~90% of all BRAF mutations.

In our latest study, we designed and evaluated a new series of thioxo–tetrahydro–pyrimidine–benzenesulfonamide compounds (P01–P16), inspired by second-generation BRAF inhibitors.